Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $7.83 Average PT from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $7.83.

Several analysts have recently weighed in on AQST shares. SVB Leerink started coverage on shares of Aquestive Therapeutics in a research report on Friday, May 10th. They set an “outperform” rating and a $8.00 target price on the stock. Piper Sandler started coverage on shares of Aquestive Therapeutics in a research report on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price target on the stock. JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, June 5th. Finally, Raymond James began coverage on shares of Aquestive Therapeutics in a research report on Thursday, March 28th. They set an “outperform” rating and a $7.00 target price on the stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Aquestive Therapeutics in the first quarter valued at approximately $54,000. Lazard Asset Management LLC boosted its holdings in Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares during the last quarter. Jump Financial LLC acquired a new position in Aquestive Therapeutics during the fourth quarter worth $60,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Aquestive Therapeutics by 14.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after purchasing an additional 30,898 shares during the last quarter. Finally, PFG Investments LLC acquired a new position in Aquestive Therapeutics during the first quarter worth $204,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock opened at $2.45 on Friday. The firm’s 50-day simple moving average is $3.06 and its 200-day simple moving average is $3.20. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The firm has a market cap of $223.05 million, a P/E ratio of -5.83 and a beta of 2.81.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The firm had revenue of $12.05 million for the quarter, compared to analyst estimates of $12.22 million. During the same quarter in the prior year, the business posted $0.11 EPS. On average, equities analysts forecast that Aquestive Therapeutics will post -0.49 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.